Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Real-world retrospective single-center analysis showing LIPI independently predicts survival in nivolumab-treated advanced NSCLC with statistically significant stratification and improved model discrimination, but limited by retrospective design, single center, and lack of external validation.
A machine learning signature study with in vitro validation of a candidate gene, but lacking prospective clinical validation, hard clinical endpoints, or therapeutic trial data to support clinical implementation.
This is a mechanistic study using computational and functional approaches to characterize a non-coding RNA's role in cancer, raising questions about therapeutic potential rather than testing clinical efficacy or providing definitive evidence of practice-changing utility.
Multi-scale computational prediction of a candidate mutp53-FOXP3 interaction mechanism, supported by associational survival data and in silico modelling but lacking experimental validation of physical sequestration or functional causality.
This is a narrative review synthesizing observational associations and mechanistic hypotheses about the gut–prostate axis without reporting original trial data, causal evidence, or effect sizes.
Meta-analysis of public transcriptomic data identifying candidate biomarkers and immune signatures associated with neoadjuvant response in rectal cancer, but without clinical validation, prospective design, or outcome prediction model.
A sound methodological study demonstrating improved prediction accuracy across multiple cancer cohorts using a novel filtering approach, but limited by lack of prospective validation, absence of hard clinical outcomes, and no comparison to established biomarkers.
A well-designed retrospective proteogenomic study with independent validation cohort showing that proteomic profiling improves risk stratification beyond clinical-genomic classifiers in high-risk endometrial cancer, but limited by single-center design, archival tissue, and lack of prospective validation or intervention outcome data.